Last updated: March 2026
Tesofensine blocks serotonin, dopamine, and norepinephrine reuptake simultaneously — a mechanism no approved weight-loss drug uses. Originally developed for Alzheimer's and Parkinson's, Phase 3 obesity trials showed ~10% body weight loss over 24 weeks. Not FDA approved.
Tesofensine is a presynaptic monoamine reuptake inhibitor — it blocks the reuptake transporters for serotonin (SERT), dopamine (DAT), and norepinephrine (NET) simultaneously. This triple action suppresses appetite, increases metabolic rate, and reduces food reward signaling, all through different pathways than existing drugs.
Unlike stimulants (which release monoamines) or SSRIs (which only target serotonin), tesofensine blocks all three reuptake transporters. DAT inhibition reduces food reward; SERT inhibition increases satiety signaling; NET inhibition increases sympathetic tone and thermogenesis. The combination produces additive appetite suppression without the tolerance seen with single-target agents.
Tesofensine acts centrally on the hypothalamic circuits that regulate hunger. Elevated dopamine in the nucleus accumbens reduces hedonic eating (eating for reward rather than hunger). Elevated serotonin activates 5-HT2C receptors in the hypothalamus, reducing meal size and overall caloric intake. Studies show a consistent 10-20% reduction in daily caloric intake.
Norepinephrine reuptake inhibition increases sympathetic nervous system activation, similar to low-dose beta-adrenergic stimulation. This elevates resting metabolic rate, increases thermogenesis in brown adipose tissue, and slightly elevates heart rate (~7 bpm). This metabolic component contributes to weight loss independent of appetite reduction.
Tesofensine was originally developed by NeuroSearch for Alzheimer's and Parkinson's disease. When Phase 2 neurodegeneration trials failed to meet endpoints, researchers noticed significant weight loss in treated patients. This led to deliberate repurposing for obesity, with Phase 2 and Phase 3 trials demonstrating superior weight loss versus all approved agents at the time of the 2008 TIPO-1 publication.
Data from the TIPO-1 Phase 2 trial (Sjödin et al., The Lancet, 2008) — 203 obese adults, 24-week treatment with placebo, 0.25mg, 0.5mg, or 1.0mg tesofensine daily.
Adverse event incidence from TIPO-1 trial at the 0.5mg dose. Many effects reflect the sympathomimetic and dopaminergic mechanism.
Monitoring and support supplies for metabolic health research.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and research purposes only. Tesofensine is not FDA approved in the United States as of 2026. It is an investigational compound. This is not medical advice. Never use any compound without direct supervision from a licensed healthcare provider. Clinical data cited from published peer-reviewed literature.